Answers are grounded in this paper and cite their sources.
This research develops a photocrosslinkable extracellular matrix for enhanced drug screening in osteosarcoma models, suggesting improved personalized medicine applications.
Osteosarcoma (OS), the most common malignant bone cancer in children and adolescents, has a five-year survival rate of 60% for primary cases and only 20% for metastatic cases. Despite decades of research, treatment options remain largely unchanged. Personalised models, such as patient-derived organoids (PDOs), promise to advance drug discovery to develop as end-goal patient-specific treatment concepts. Still, current approaches lack key extracellular matrix (ECM) components essential to mimic the tumour microenvironment more closely. This study aims to develop a bone-specific, photocrosslinkable ECM-based in vitro platform to enhance current capabilities in drug screening in OS. Porcine bones were demineralised with EDTA, and decellularisation methods were compared using sodium lauryl ether sulfate (SLES), Triton-X-100, their combination, and sodium chloride-induced osmotic shock. DNA quantification and haematoxylin and eosin staining confirmed successful decellularisation, with SLES and osmotic shock showing the highest efficiency, while osmotic shock demonstrated the best cytocompatibility. Glycosaminoglycan quantification and proteomics analysis demonstrated preserved ECM components, resembling some of the features of native tissue. The ECM was solubilised and functionalised with methacryloyl groups to create photocrosslinkable hydrogels with tuneable mechanical properties. Human osteoblasts (hOBs) encapsulated in dECM-MA hydrogels with Young's 5, 10, and 20 kPa moduli showed over 90% viability over an eight-week culture period. At 10 kPa, differentiation markers such as alkaline phosphatase (ALP) were elevated compared to the GelMA control. Morphologically, hOBs in dECM-MA displayed larger, more spread cells with extended lamellipodia. Future work will incorporate OS-PDOs into the dECM-MA platform to model OS and evaluate drug responses. Ultimately, this bone-specific ECM model has the potential to advance personalized medicine by facilitating the functional characterization of osteosarcoma (OS) and the screening of patient-specific therapies.
No takes yet. Share an insight, caveat, or question.
Dekker et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: